| A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2767 | 2017 |
| BDDCS, the Rule of 5 and drugability LZ Benet, CM Hosey, O Ursu, TI Oprea Advanced drug delivery reviews 101, 89-98, 2016 | 1113 | 2016 |
| Unexplored therapeutic opportunities in the human genome TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ... Nature reviews Drug discovery 17 (5), 317-332, 2018 | 469 | 2018 |
| Drug repurposing from an academic perspective TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ... Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011 | 430 | 2011 |
| Probe reports from the NIH molecular libraries program Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ... Bethesda (MD), 2010 | 368 | 2010 |
| DrugCentral: online drug compendium O Ursu, J Holmes, J Knockel, CG Bologa, JJ Yang, SL Mathias, SJ Nelson, ... Nucleic acids research, gkw993, 2016 | 366 | 2016 |
| Understanding drug‐likeness O Ursu, A Rayan, A Goldblum, TI Oprea Wiley interdisciplinary reviews: computational molecular Science 1 (5), 760-781, 2011 | 343 | 2011 |
| Pharos: collating protein information to shed light on the druggable genome DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, ... Nucleic acids research 45 (D1), D995-D1002, 2017 | 299 | 2017 |
| DrugCentral 2021 supports drug discovery and repositioning S Avram, CG Bologa, J Holmes, G Bocci, TB Wilson, DT Nguyen, ... Nucleic acids research 49 (D1), D1160-D1169, 2021 | 211 | 2021 |
| Characterization of a Cdc42 protein inhibitor and its use as a molecular probe L Hong, SR Kenney, GK Phillips, D Simpson, CE Schroeder, J Nöth, ... Journal of Biological Chemistry 288 (12), 8531-8543, 2013 | 199 | 2013 |
| DrugCentral 2018: an update O Ursu, J Holmes, CG Bologa, JJ Yang, SL Mathias, V Stathias, ... Nucleic acids research 47 (D1), D963-D970, 2019 | 158 | 2019 |
| A potent and selective inhibitor of Cdc42 GTPase Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ... Probe Reports from the NIH Molecular Libraries Program [Internet], 2010 | 158 | 2010 |
| A crowdsourcing evaluation of the NIH chemical probes TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ... Nature chemical biology 5 (7), 441-447, 2009 | 145 | 2009 |
| Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer‐aided drug repurposing TI Oprea, SK Nielsen, O Ursu, JJ Yang, O Taboureau, SL Mathias, ... Molecular informatics 30 (2‐3), 100-111, 2011 | 132 | 2011 |
| A Competitive Nucleotide Binding Inhibitor: In Vitro Characterization of Rab7 GTPase Inhibition JO Agola, L Hong, Z Surviladze, O Ursu, A Waller, JJ Strouse, ... ACS chemical biology 7 (6), 1095-1108, 2012 | 122 | 2012 |
| Badapple: promiscuity patterns from noisy evidence JJ Yang, O Ursu, CA Lipinski, LA Sklar, TI Oprea, CG Bologa Journal of cheminformatics 8 (1), 29, 2016 | 107 | 2016 |
| Drug target ontology to classify and integrate drug discovery data Y Lin, S Mehta, H Küçük-McGinty, JP Turner, D Vidovic, M Forlin, A Koleti, ... Journal of biomedical semantics 8 (1), 50, 2017 | 86 | 2017 |
| Omega polynomial in tubular nanostructures MV Diudea, S Cigher, AE Vizitiu, O Ursu, PE John Croatica chemica acta 79 (3), 445-448, 2006 | 83 | 2006 |
| Discovery of a specific inhibitor of human GLUT5 by virtual screening and in vitro transport evaluation AM George Thompson, O Ursu, P Babkin, CV Iancu, A Whang, TI Oprea, ... Scientific reports 6 (1), 24240, 2016 | 78 | 2016 |
| Emerging trends in the discovery of natural product antibacterials CG Bologa, O Ursu, TI Oprea, CE Melançon III, GP Tegos Current Opinion in Pharmacology 13 (5), 678-687, 2013 | 78 | 2013 |
Tudor OpreaCEO, Expert Systems IncVerified email at expertsystems.inc
